Match!
Seabastian Schneeweiss
Harvard University
528Publications
83H-index
24.4kCitations
Publications 527
Newest
#1Jessica M. Franklin (Brigham and Women's Hospital)H-Index: 25
#2Ajinkya Pawar (Brigham and Women's Hospital)H-Index: 4
Last.Seabastian Schneeweiss (Brigham and Women's Hospital)H-Index: 83
view all 7 authors...
Source
#1Anton Pottegård (University of Southern Denmark)H-Index: 22
#2Olaf H. Klungel (UU: Utrecht University)H-Index: 48
Last.Alison BourkeH-Index: 3
view all 12 authors...
Source
#1Michael Fralick (U of T: University of Toronto)H-Index: 11
#2Seabastian Schneeweiss (Brigham and Women's Hospital)H-Index: 83
Last.Aaron S. Kesselheim (Brigham and Women's Hospital)H-Index: 42
view all 5 authors...
Background Desmopressin was approved by the Food and Drug Administration (FDA) in 1978 for use in diabetes insipidus and bleeding disorders, but it is also prescribed off-label for patients with nocturia. Quantifying the potential risks facing adult patients taking desmopressin has taken on added importance because a new intranasal formulation of desmopressin was approved by the FDA in 2017. Like the old formulation, the main active ingredient is desmopressin acetate, but the new formulation als...
Source
#2Seabastian Schneeweiss (Brigham and Women's Hospital)H-Index: 83
Last.Saira Jan (RU: Rutgers University)
view all 5 authors...
Source
#1Seabastian Schneeweiss (Brigham and Women's Hospital)H-Index: 83
#2Peggy L. Carver (UM: University of Michigan)H-Index: 24
Last.Am WalkerH-Index: 73
view all 18 authors...
Source
#1Ajinkya Pawar (Brigham and Women's Hospital)H-Index: 4
#2Elisabetta Patorno (Brigham and Women's Hospital)H-Index: 18
Last.Mehdi Najafzadeh (Brigham and Women's Hospital)H-Index: 16
view all 9 authors...
Source
#1Robert J. Glynn (Brigham and Women's Hospital)H-Index: 124
#2Mark Lunt (University of Manchester)H-Index: 66
Last.Til Stürmer (UNC: University of North Carolina at Chapel Hill)H-Index: 56
view all 6 authors...
Source
#1Seoyoung C. Kim (Brigham and Women's Hospital)H-Index: 30
#2Ajinkya Pawar (Brigham and Women's Hospital)H-Index: 4
Last.Seabastian Schneeweiss (Brigham and Women's Hospital)H-Index: 83
view all 8 authors...
Abstract Objectives To examine the rate of incident malignancies excluding non-melanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA) newly treated with tocilizumab versus other biologic drugs. Methods We conducted a cohort study using data from 3 U.S. insurance claims databases – Medicare (2010–2015), ‘IMS’ PharMetrics Plus (2011–2015) and Truven ‘MarketScan’ (2011–2015). Adults with RA who newly started tocilizumab or a TNF inhibitor (TNFi) after failing a different TNFi, abata...
Source
#1Dae Hyun Kim (Brigham and Women's Hospital)H-Index: 32
#2Elisabetta Patorno (Brigham and Women's Hospital)H-Index: 18
Last.Robert J. Glynn (Brigham and Women's Hospital)H-Index: 124
view all 6 authors...
Source
#1Seabastian Schneeweiss (Brigham and Women's Hospital)H-Index: 83
#2Samy Suissa (McGill University)H-Index: 85
Source
12345678910